ATRA Stock Recent News

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.31 per share a year ago.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. PDT / 7.

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.

In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.

Atara Biotherapeutics has complications with the FDA while the EU approach is so much clearer. The MS drug is a value driver if ATRA sorts out issues.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pascal Touchon - President and Chief Executive Officer Dr. Jakob Dupont - Executive Vice President and Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Dr. AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Group John Newman - Canaccord Phil Nadeau - Cowen and Company Kallie Briza - Stifel Jessica Hui - Evercore Operator Good afternoon, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics Third Quarter 2022 Financial Results Conference Call.

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are you using these trends to make money with penny stocks? The post Stock Market Trends, Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.